Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance
出版年份 2022 全文链接
标题
Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance
作者
关键词
-
出版物
Antibiotics-Basel
Volume 11, Issue 6, Pages 723
出版商
MDPI AG
发表日期
2022-05-28
DOI
10.3390/antibiotics11060723
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- In vitro Antibacterial Activity of Cefiderocol against Recent Multidrug-Resistant Carbapenem-nonsusceptible Enterobacterales Isolates
- (2022) Qingyu Zhang et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants
- (2022) Laurent Poirel et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- In search for a synergistic combination against pandrug-resistant A. baumannii; methodological considerations
- (2022) Stamatis Karakonstantis et al. INFECTION
- Relationship of TonB-dependent receptors with susceptibility to cefiderocol in clinical isolates of Pseudomonas aeruginosa
- (2022) Aanchal Gupta et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials
- (2022) Patrice Nordmann et al. Microbial Drug Resistance
- Proteomic and Transcriptomic Analyses Indicate Reduced Biofilm-Forming Abilities in Cefiderocol-Resistant Klebsiella pneumoniae
- (2022) Jinfeng Bao et al. Frontiers in Microbiology
- Assessment of In Vitro Cefiderocol Susceptibility and Comparators against an Epidemiologically Diverse Collection of Acinetobacter baumannii Clinical Isolates
- (2022) Clara Ballesté-Delpierre et al. Antibiotics-Basel
- Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii
- (2022) Marco Falcone et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Impact of Acquired Broad-Spectrum β-Lactamases on Susceptibility to Cefiderocol and Newly Developed β-Lactam/β-Lactamase Inhibitor Combinations in Escherichia coli and Pseudomonas aeruginosa
- (2022) Laurent Poirel et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Emergence of High-Level Cefiderocol Resistance in Carbapenem-Resistant Klebsiella pneumoniae from Bloodstream Infections in Patients with Hematologic Malignancies in China
- (2022) Peng Lan et al. Microbiology Spectrum
- Human Serum Proteins and Susceptibility of Acinetobacter baumannii to Cefiderocol: Role of Iron Transport
- (2022) Casin Le et al. Biomedicines
- Evolution of Cefiderocol Non-Susceptibility in Pseudomonas aeruginosa in a Patient Without Previous Exposure to the Antibiotic
- (2021) Ana Paula Streling et al. CLINICAL INFECTIOUS DISEASES
- Cross-resistance to cefiderocol and ceftazidime–avibactam in KPC β-lactamase mutants and the inoculum effect
- (2021) Claire Amaris Hobson et al. CLINICAL MICROBIOLOGY AND INFECTION
- Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens
- (2021) Jacob E Choby et al. LANCET INFECTIOUS DISEASES
- Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-, cefiderocol-resistant ST-512 Klebsiella pneumoniae producing KPC-31, a D179Y variant of KPC-3
- (2021) Giusy Tiseo et al. Open Forum Infectious Diseases
- The highly dynamic nature of bacterial heteroresistance impairs its clinical detection
- (2021) Cátia Pereira et al. Communications Biology
- Case Report and Genomic Analysis of Cefiderocol-Resistant Escherichia coli Clinical Isolates
- (2021) Travis K Price et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Contribution of PER-Type and NDM-Type β-Lactamases to Cefiderocol Resistance in Acinetobacter baumannii
- (2021) Laurent Poirel et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Antibacterial Activity of Cefiderocol against Multidrug-Resistant Acinetobacter baumannii
- (2021) Jacinda C. Abdul-Mutakabbir et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Rapid Development of Cefiderocol Resistance in Carbapenem-resistant Enterobacter cloacae During Therapy Is Associated With Heterogeneous Mutations in the Catecholate Siderophore Receptor cirA
- (2021) Sabrina Klein et al. CLINICAL INFECTIOUS DISEASES
- In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection
- (2021) Francisco Javier Candel et al. CLINICAL MICROBIOLOGY AND INFECTION
- In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects
- (2021) Gabriele Bianco et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Discrepancy in sustained efficacy and resistance emergence under human-simulated exposure of cefiderocol against Stenotrophomonas maltophilia between in vitro chemostat and in vivo murine infection models
- (2021) Christian M Gill et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- No in vitro activity of cefiderocol against OXA-427-producing Enterobacterales
- (2021) Ann-Sophie Jacob et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Pan-drug resistant Providencia rettgeri contributing to a fatal case of COVID-19
- (2021) Patrick Mc Gann et al. JOURNAL OF MEDICAL MICROBIOLOGY
- Placing in-vitro heteroresistance in the context of clinical results
- (2021) Matteo Bassetti et al. LANCET INFECTIOUS DISEASES
- Cefiderocol Activity Against Clinical Pseudomonas aeruginosa Isolates Exhibiting Ceftolozane-Tazobactam Resistance
- (2021) Patricia J Simner et al. Open Forum Infectious Diseases
- New Delhi Metallo-Beta-Lactamase Facilitates the Emergence of Cefiderocol Resistance in Enterobacter cloacae
- (2021) Dennis Nurjadi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019
- (2021) James A. Karlowsky et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Progressive Development of Cefiderocol Resistance in Escherichia coli During Therapy is Associated With an Increase in blaNDM-5 Copy Number and Gene Expression
- (2021) Patricia J Simner et al. CLINICAL INFECTIOUS DISEASES
- Role of AxyABM overexpression in acquired resistance in Achromobacter xylosoxidans
- (2021) Arnaud Magallon et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Defining Baseline Mechanisms of Cefiderocol Resistance in the Enterobacterales
- (2021) Patricia J. Simner et al. Microbial Drug Resistance
- A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol
- (2021) Milo Gatti et al. Journal of Global Antimicrobial Resistance
- In Vitro Evolution of Cefiderocol Resistance in an NDM-Producing Klebsiella pneumoniae Due to Functional Loss of CirA
- (2021) Christi L. McElheny et al. Microbiology Spectrum
- Systematic Review of Antimicrobial Combination Options for Pandrug-Resistant Acinetobacter baumannii
- (2021) Stamatis Karakonstantis et al. Antibiotics-Basel
- Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?
- (2021) Jacob E Choby et al. Lancet Microbe
- Characterisation of cefiderocol-non-susceptible Acinetobacter baumannii isolates from Taiwan
- (2021) Yoshinori Yamano et al. Journal of Global Antimicrobial Resistance
- Activity of Cefiderocol and Comparators against Isolates from Cancer Patients
- (2020) Kenneth V.I. Rolston et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units
- (2020) Alyssa R. Golden et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Activity of Cefiderocol Against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii Endemic to Medical Centers in New York City
- (2020) Alejandro Iregui et al. Microbial Drug Resistance
- Structural basis of reduced susceptibility to ceftazidime–avibactam and cefiderocol in Enterobacter cloacae due to AmpC R2 loop deletion
- (2020) Akito Kawai et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical evolution of AmpC-mediated ceftazidime-avibactam and cefiderocol resistance in Enterobacter cloacae complex following exposure to cefepime
- (2020) Ryan K Shields et al. CLINICAL INFECTIOUS DISEASES
- Colistin heteroresistance in Acinetobacter spp.: systematic review and meta-analysis of the prevalence and discussion of the mechanisms and potential therapeutic implications
- (2020) Stamatis Karakonstantis et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- A systematic review of implications, mechanisms, and stability of in vivo emergent resistance to colistin and tigecycline in Acinetobacter baumannii
- (2020) Stamatis Karakonstantis JOURNAL OF CHEMOTHERAPY
- In vitro activity of cefiderocol, a siderophore-cephalosporin, against multidrug-resistant gram-negative bacteria
- (2020) Shazad Mushtaq et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cefiderocol Resistance in Acinetobacter baumannii: Roles of β-Lactamases, Siderophore Receptors, and Penicillin Binding Protein 3
- (2020) Saquib Malik et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-Negative infections in ICU patients
- (2020) Marco Falcone et al. CLINICAL INFECTIOUS DISEASES
- Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems
- (2020) Stamatis Karakonstantis et al. INFECTION
- Cefiderocol Antimicrobial Susceptibility Testing against Multidrug-Resistant Gram-negative Bacilli: A Comparison of Disk Diffusion to Broth Microdilution
- (2020) C. Paul Morris et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Excess mortality due to pandrug-resistant Acinetobacter baumannii infections in hospitalized patients
- (2020) S. Karakonstantis et al. JOURNAL OF HOSPITAL INFECTION
- Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
- (2020) Matteo Bassetti et al. LANCET INFECTIOUS DISEASES
- Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
- (2020) Richard G Wunderink et al. LANCET INFECTIOUS DISEASES
- Compassionate use of cefiderocol in a pancreatic abscess and emergence of resistance
- (2020) C. Grande Perez et al. MEDECINE ET MALADIES INFECTIEUSES
- A Fundamental Change in Antibiotic Susceptibility Testing Would Better Prevent Therapeutic Failure: From Individual to Population-Based Analysis
- (2020) Ivan Brukner et al. Frontiers in Microbiology
- Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014)
- (2020) Naoki Kohira et al. Journal of Global Antimicrobial Resistance
- Mechanisms and clinical relevance of bacterial heteroresistance
- (2019) Dan I. Andersson et al. NATURE REVIEWS MICROBIOLOGY
- Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin
- (2019) Takafumi Sato et al. CLINICAL INFECTIOUS DISEASES
- Pandrug-resistant Gram-negative bacteria: a systematic review of current epidemiology, prognosis and treatment options
- (2019) Stamatis Karakonstantis et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens – The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study
- (2019) Matteo Bassetti et al. Infection and Drug Resistance
- TonB-Dependent Receptor Repertoire of Pseudomonas aeruginosa for Uptake of Siderophore-Drug Conjugates
- (2018) Alexandre Luscher et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship
- (2018) Toshiaki Aoki et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- OUP accepted manuscript
- (2018) JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Efficacy of Humanized Cefiderocol Exposures Over 72 hours Against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model
- (2018) Sean M Stainton et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015
- (2018) James A. Karlowsky et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Stability of cefiderocol against clinically significant broad-spectrum oxacillinases
- (2018) Laurent Poirel et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)
- (2018) Krystyna M. Kazmierczak et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- 696. Mechanism of Cefiderocol high MIC mutants obtained in non-clinical FoR studies
- (2018) Akinobu Ito et al. Open Forum Infectious Diseases
- OXA-427, a new plasmid-borne carbapenem-hydrolysing class D β-lactamase in Enterobacteriaceae
- (2017) Pierre Bogaerts et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Antimicrobial Heteroresistance: an Emerging Field in Need of Clarity
- (2015) Omar M. El-Halfawy et al. CLINICAL MICROBIOLOGY REVIEWS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started